Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Partanen group

Children who experience cancer may develop neurocognitive impairments after treatment. Our group focuses on the early identification and intervention of these impairments using a combination of neuropsychological and neuroimaging measures. These studies will ultimately help to prevent further neuropsychological difficulties in patients and survivors of cancer. 

PI: Dr. Marita Partanen
Phone 088 97 25 844



 

“Identifying neuropsychological problems early are the key to preventing them”  Dr. Marita Partanen - PI

 

Screening of neuropsychological impairments

Cognitive skills may be impacted after treatment for cancer. A change in overall IQ or related domains may impact a child’s quality of life during and after treatment. These cognitive deficits may be caused by various factors, but it is possible to detect these deficits early in treatment or survivorship. One aim of our research is to identify neuropsychological impairments in patients with cancer using a longitudinal screening battery.

Neurobiological bases of neuropsychological impairments

 Declines in cognitive performance have been associated with white matter impairments in the brain. Other subtle changes can be detected with neuroimaging, which can provide further insight into the neurobiological substrates of and interventions for cognitive deficits in pediatric oncology. One aim of our research is to determine whether vascular, structural, or functional changes in the brain are associated with neurocognitive functioning in patients with cancer

Partanen group